Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China

Table 3 Bedaquiline success rate and market penetration/adoption inputs utilized for scenario analysis

Parameter		Scenario 1		Scenario 2
Success rate of first line (LOT1) treatment of DR-TB with bedaquiline		61%		80%
Peak utilization of bedaquiline-containing regimens in DR-TB treated patients	LOT1	85%		85%
	LOT2^a	17%		28%
Treatment start date		2020-Q1
		2020	2021	2022	2023	2024
Adoption of bedaquiline-containing regimens in DR-TB patients (treated with short or long course regimen)		60%	70%	80%	85%	85%

^aPatients failing LOT1 treatment with bedaquiline were assumed to be ineligible for re-treatment with bedaquiline in LOT2, while 85% of patients not treated with bedaquiline in LOT1 were assumed to be treated with bedaquiline in LOT2 in both scenarios
Abbreviations: LOT line of treatment; DR-TB drug resistant tuberculosis; Q quarter of the year

ISSN: 1471-2334